News
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback